The impact of flash glucose monitoring on glycated hemoglobin in type 2 diabetes managed with basal insulin in Canada: A retrospective real-world chart review study.

IF 2.8 4区医学 Q3 ENDOCRINOLOGY & METABOLISM

Diabetes & Vascular Disease Research Pub Date : 2021-07-01 DOI:10.1177/14791641211021374

Tom Elliott, Sorin Beca, Rajendra Beharry, Michael A Tsoukas, Alexandro Zarruk, Alexander Abitbol

{"title":"The impact of flash glucose monitoring on glycated hemoglobin in type 2 diabetes managed with basal insulin in Canada: A retrospective real-world chart review study.","authors":"Tom Elliott, Sorin Beca, Rajendra Beharry, Michael A Tsoukas, Alexandro Zarruk, Alexander Abitbol","doi":"10.1177/14791641211021374","DOIUrl":null,"url":null,"abstract":"Background: The real-world effect of intermittently scanned continuous glucose monitoring on glucose control in type 2 diabetes treated with basal insulin is uncertain. This retrospective real-world study aimed to evaluate change in glycated hemoglobin (HbA1c) amongst adults with type 2 diabetes managed with basal insulin starting flash glucose monitoring.Methods: Medical records were reviewed for adults with type 2 diabetes treated with basal insulin for ⩾1 year and using FreeStyle LibreTM Flash Glucose Monitoring for ⩾3 months. Prior to device use an HbA1c 8.0%-12.0% was recorded and a further HbA1c result was recorded 3-6 months (90-194 days) after starting device use.Results: Medical records (n = 91) analyzed from six Canadian diabetes centers showed HbA1c significantly decreased by 0.8% ± 1.1 (mean ± SD, [p < 0.0001]) from mean baseline HbA1c 8.9% ± 0.9 to 8.1% ± 1.0 at 3-6 months after initiating flash glucose monitoring. HbA1c improvement was not independently associated with age, BMI, insulin use duration, or sex.Conclusion: This Canadian real-world retrospective study showed significantly reduced HbA1c following initiation of ﬂash glucose monitoring technology to further support management of type 2 diabetes treated with basal insulin.","PeriodicalId":11092,"journal":{"name":"Diabetes & Vascular Disease Research","volume":"18 4","pages":"14791641211021374"},"PeriodicalIF":2.8000,"publicationDate":"2021-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/14791641211021374","citationCount":"16","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetes & Vascular Disease Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/14791641211021374","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 16

Abstract

Background: The real-world effect of intermittently scanned continuous glucose monitoring on glucose control in type 2 diabetes treated with basal insulin is uncertain. This retrospective real-world study aimed to evaluate change in glycated hemoglobin (HbA1c) amongst adults with type 2 diabetes managed with basal insulin starting flash glucose monitoring.

Methods: Medical records were reviewed for adults with type 2 diabetes treated with basal insulin for ⩾1 year and using FreeStyle Libre^TM Flash Glucose Monitoring for ⩾3 months. Prior to device use an HbA1c 8.0%-12.0% was recorded and a further HbA1c result was recorded 3-6 months (90-194 days) after starting device use.

Results: Medical records (n = 91) analyzed from six Canadian diabetes centers showed HbA1c significantly decreased by 0.8% ± 1.1 (mean ± SD, [p < 0.0001]) from mean baseline HbA1c 8.9% ± 0.9 to 8.1% ± 1.0 at 3-6 months after initiating flash glucose monitoring. HbA1c improvement was not independently associated with age, BMI, insulin use duration, or sex.

Conclusion: This Canadian real-world retrospective study showed significantly reduced HbA1c following initiation of ﬂash glucose monitoring technology to further support management of type 2 diabetes treated with basal insulin.

Abstract Image

查看原文本刊更多论文

加拿大基础胰岛素治疗的2型糖尿病患者瞬时血糖监测对糖化血红蛋白的影响:一项回顾性现实世界图表回顾研究。

背景:间歇性扫描连续血糖监测对基础胰岛素治疗的2型糖尿病患者血糖控制的实际效果尚不确定。本回顾性现实世界研究旨在评估2型糖尿病成人患者糖化血红蛋白(HbA1c)在基础胰岛素启动瞬时血糖监测中的变化。方法:对使用基础胰岛素治疗的2型糖尿病成人患者的医疗记录进行了回顾，并使用FreeStyle LibreTM Flash血糖监测进行了大于或小于3个月的治疗。设备使用前HbA1c记录为8.0%-12.0%，开始使用设备后3-6个月(90-194天)记录进一步的HbA1c结果。结果:来自加拿大6个糖尿病中心的医疗记录(n = 91)分析显示，HbA1c显著降低了0.8%±1.1(平均值±SD)。[p]结论:这项加拿大现实世界的回顾性研究显示，在开始使用瞬时血糖监测技术以进一步支持基础胰岛素治疗的2型糖尿病的管理后，HbA1c显著降低。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Diabetes & Vascular Disease Research ENDOCRINOLOGY & METABOLISM-PERIPHERAL VASCULAR DISEASE

CiteScore

4.40

自引率

0.00%

发文量

审稿时长

>12 weeks

期刊介绍： Diabetes & Vascular Disease Research is the first international peer-reviewed journal to unite diabetes and vascular disease in a single title. The journal publishes original papers, research letters and reviews. This journal is a member of the Committee on Publication Ethics (COPE)